Heartflow, Inc.

HeartFlow, Inc. is a medical technology company that provides non-invasive solutions for diagnosing and managing coronary artery diseases. Its flagship HeartFlow Platform uses artificial intelligence and computational fluid dynamics to create a personalized 3D model of a patient's heart from a single coronary computed tomography angiography scan. The company offers several products under this platform: HeartFlow RoadMap Analysis provides an intuitive anatomic visualization of the coronary arteries; HeartFlow FFRCT Analysis calculates blood flow and pinpoints clinically significant blockages; and HeartFlow Plaque Analysis offers a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. These tools help overcome the limitations of traditional non-invasive imaging tests by providing insights on blood flow, stenosis, and plaque volume and composition.

HeartFlow, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol HTFL. Its shares are traded in United States Dollars (USD). The company is headquartered in San Francisco, California, and operates primarily in the United States and globally.

HeartFlow, Inc. operates in the Healthcare sector and is classified under the Health Information Services industry. This means the company focuses on using technology and data to improve healthcare delivery, specifically in the field of cardiovascular diagnostics. Its products leverage AI and computational fluid dynamics to analyze medical imaging data, providing actionable insights for physicians treating coronary artery disease.

HeartFlow, Inc. is headquartered in San Francisco, California, United States. The company serves both the United States and global markets. Its non-invasive diagnostic solutions are used by healthcare providers worldwide to diagnose and manage coronary artery disease. The company was originally incorporated in 2007 as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009.

HeartFlow generates revenue by providing its non-invasive diagnostic platform to healthcare providers. The company's HeartFlow Platform uses AI and computational fluid dynamics to create personalized 3D heart models from coronary CT angiography scans. It offers three main analyses: RoadMap Analysis for anatomic visualization, FFRCT Analysis for blood flow calculation and blockage identification, and Plaque Analysis for comprehensive plaque assessment. These tools help clinicians make more informed treatment decisions for coronary artery disease, potentially reducing the need for invasive procedures. The company likely charges per analysis or through subscription agreements with hospitals and clinics, though specific pricing details are not provided in the available data.